Antihypertensive effect of irbesartan and predictors of response in obesity-associated hypertension : a prospective, open-label study
- PMID: 17532722
- DOI: 10.2165/00044011-200525120-00003
Antihypertensive effect of irbesartan and predictors of response in obesity-associated hypertension : a prospective, open-label study
Abstract
Background: Obesity-associated hypertension is difficult to treat and puts patients at a substantially increased risk of cardiovascular events. Irbesartan has previously been shown to effectively lower blood pressure (BP) in high-risk groups including patients with type 2 diabetes mellitus or nephropathy, and may therefore also be suitable for the treatment of obesity-associated hypertension. In this study we aimed to: (a) assess the efficacy and tolerability of irbesartan alone and in combination with hydrochlorothiazide in patients with obesity-associated mild-to-moderate hypertension; and (b) investigate patient-associated determinants of poor BP control in this patient group.
Patients and methods: This was a 3-month, prospective, open-label, multicentre, phase IV study in 72 479 hypertensive patients in 6989 general practices across Germany. Main outcome measures were BP reduction (primary parameter of effectiveness) and BP response rates after 3 months, as well as adverse events (AEs). Independent predictors of poor control were identified in a multivariate proportional odds model.
Results: All of the patients were Caucasian, 50.5% were females, mean age was 62.1 +/- 11.1 years, mean bodyweight was 88.6 +/- 15.4kg, and mean body mass index (BMI) was 30.7 +/- 4.8 kg/m(2). Almost all the patients were overweight or obese (92.3%). From a baseline value of 162/94mm Hg, systolic and diastolic BP were reduced by a mean of -23/-12mm Hg after 3 months. 66.1% of the patients were responders (reduction of diastolic BP >/=10mm Hg), and 48.0% achieved BP normalisation (i.e. <140/90mm Hg). 79% of patients met their individual treatment goals as defined by the treating physician (mean 135/80mm Hg). AEs were reported in only 322 patients (0.4%). Factors requiring special attention in patients not achieving BP control were age (>55 years), high BMI category (>25 kg/m(2)), and increased waist circumference.
Conclusion: Treatment with irbesartan (+/- hydrochlorothiazide) appeared to be effective and well tolerated in the study population of patients with obesity- associated hypertension. Easily recognisable characteristics allow physicians to identify patients whose BP is likely to be difficult to control.
Similar articles
-
Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.Clin Ther. 2008 Dec;30(12):2354-65. doi: 10.1016/j.clinthera.2008.12.018. Clin Ther. 2008. PMID: 19167594 Clinical Trial.
-
A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review.Postgrad Med. 2011 Jul;123(4):126-34. doi: 10.3810/pgm.2011.07.2312. Postgrad Med. 2011. PMID: 21680997 Clinical Trial.
-
Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.Clin Drug Investig. 2007;27(8):545-58. doi: 10.2165/00044011-200727080-00003. Clin Drug Investig. 2007. PMID: 17638395 Clinical Trial.
-
Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.Curr Med Res Opin. 2005 Sep;21(9):1433-40. doi: 10.1185/030079905X61811. Curr Med Res Opin. 2005. PMID: 16197662
-
Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.Drugs. 2004;64(9):999-1028. doi: 10.2165/00003495-200464090-00011. Drugs. 2004. PMID: 15101793 Review.
Cited by
-
Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors.J Clin Hypertens (Greenwich). 2010 Jul 1;12(7):487-94. doi: 10.1111/j.1751-7176.2010.00294.x. J Clin Hypertens (Greenwich). 2010. PMID: 20629810 Free PMC article. Clinical Trial.
-
First Line CombinAtion Therapy in the Treatment of Stage II and III Hypertension (FLASH).Front Cardiovasc Med. 2020 Mar 30;7:46. doi: 10.3389/fcvm.2020.00046. eCollection 2020. Front Cardiovasc Med. 2020. PMID: 32292790 Free PMC article.
-
The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial.Clin Drug Investig. 2009;29(12):791-802. doi: 10.2165/11530600-000000000-00000. Clin Drug Investig. 2009. PMID: 19888785
-
Clinical and economic considerations of antiobesity treatment: a review of orlistat.Clinicoecon Outcomes Res. 2010;2:63-74. doi: 10.2147/ceor.s5101. Epub 2010 Jul 5. Clinicoecon Outcomes Res. 2010. PMID: 21935315 Free PMC article.
-
Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study.Cardiovasc Diabetol. 2007 Oct 2;6:28. doi: 10.1186/1475-2840-6-28. Cardiovasc Diabetol. 2007. PMID: 17910747 Free PMC article. Clinical Trial.
References
LinkOut - more resources
Full Text Sources
Miscellaneous